Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells

Nature Methods

Volumn 13, Issue 12, 2016, Pages 1029-1035

  Ma, Yunqing ^a   Zhang, Jiayuan ^a   Yin, Weijie ^a   Zhang, Zhenchao ^a   Song, Yan ^b   Chang, Xing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; BCR ABL PROTEIN; CRISPR ASSOCIATED PROTEIN; CRISPR ASSOCIATED PROTEIN 9; CYTIDINE; GENOMIC DNA; GUIDE RNA; HYBRID PROTEIN; IMATINIB; THYMINE; UNCLASSIFIED DRUG; URACIL DNA GLYCOSIDASE; AICDA (ACTIVATION-INDUCED CYTIDINE DEAMINASE); CYTIDINE DEAMINASE; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN;

ARTICLE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVE SITE; GAIN OF FUNCTION MUTATION; GENE LOCUS; GENETIC VARIABILITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN GENOME; K562 CELL LINE; MAMMAL CELL; MUTAGENESIS; MUTATIONAL ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN MOTIF; STOP CODON; CELL CULTURE TECHNIQUE; CHEMISTRY; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DRUG RESISTANCE; GENE TARGETING; GENETICS; HEK293 CELL LINE; K-562 CELL LINE; SITE DIRECTED MUTAGENESIS;

CELL CULTURE TECHNIQUES; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-ASSOCIATED PROTEINS; CYTIDINE DEAMINASE; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE TARGETING; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; IMATINIB MESYLATE; K562 CELLS; MUTAGENESIS, SITE-DIRECTED; POINT MUTATION; RECOMBINANT FUSION PROTEINS; RNA, GUIDE;

EID: 84990898361     PISSN: 15487091     EISSN: 15487105     Source Type: Journal    
DOI: 10.1038/nmeth.4027     Document Type: Article

References (43)

1. Bell, R. J. et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348, 1036-1039 (2015).
2. Daub, H., Specht, K. & Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. 3, 1001-1010 (2004).
3. Nachman, M. W. & Crowell, S. L. Estimate of the mutation rate per nucleotide in humans. Genetics 156, 297-304 (2000).
4. Takahasi, K. R., Sakuraba, Y. & Gondo, Y. Mutational pattern and frequency of induced nucleotide changes in mouse ENU mutagenesis. BMC Mol. Biol. 8, 52 (2007).
5. Di Noia, J. M. & Neuberger, M. S. Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem. 76, 1-22 (2007).
6. Peled, J. U. et al. The biochemistry of somatic hypermutation. Annu. Rev. Immunol. 26, 481-511 (2008).
7. Yoshikawa, K. et al. AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science 296, 2033-2036 (2002).
8. Mojica, F. J., Díez-Villaseñor, C., García-Martínez, J. & Soria, E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J. Mol. Evol. 60, 174-182 (2005).
9. Pourcel, C., Salvignol, G. & Vergnaud, G. CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology 151, 653-663 (2005).
10. Sorek, R., Kunin, V. & Hugenholtz, P. CRISPR-a widespread system that provides acquired resistance against phages in bacteria and archaea. Nat. Rev. Microbiol. 6, 181-186 (2008).
11. Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262-1278 (2014).
12. Doudna, J. A. & Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096 (2014).
13. Mali, P., Esvelt, K. M. & Church, G. M. Cas9 as a versatile tool for engineering biology. Nat. Methods 10, 957-963 (2013).
14. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012).
15. Barreto, V., Reina-San-Martin, B., Ramiro, A. R., McBride, K. M. & Nussenzweig, M. C. C-terminal deletion of AID uncouples class switch recombination from somatic hypermutation and gene conversion. Mol. Cell 12, 501-508 (2003).
16. Shinkura, R. et al. Separate domains of AID are required for somatic hypermutation and class-switch recombination. Nat. Immunol. 5, 707-712 (2004).
17. Martin, A. et al. Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas. Nature 415, 802-806 (2002).
18. Qi, L. S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173-1183 (2013).
19. Zheng, N. Y., Wilson, K., Jared, M. & Wilson, P. C. Intricate targeting of immunoglobulin somatic hypermutation maximizes the efficiency of affinity maturation. J. Exp. Med. 201, 1467-1478 (2005).
20. Dörner, T., Foster, S. J., Farner, N. L. & Lipsky, P. E. Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. Eur. J. Immunol. 28, 3384-3396 (1998).
21. Di Noia, J. & Neuberger, M. S. Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. Nature 419, 43-48 (2002).
22. Mol, C. D. et al. Crystal structure of human uracil-DNA glycosylase in complex with a protein inhibitor: protein mimicry of DNA. Cell 82, 701-708 (1995).
23. Jore, M. M. et al. Structural basis for CRISPR RNA-guided DNA recognition by Cascade. Nat. Struct. Mol. Biol. 18, 529-536 (2011).
24. Druker, B. J. & Lydon, N. B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105, 3-7 (2000).
25. Nardi, V., Azam, M. & Daley, G. Q. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr. Opin. Hematol. 11, 35-43 (2004).
26. Gambacorti-Passerini, C. B. et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 4, 75-85 (2003).
27. Nagar, B. et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859-871 (2003).
28. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
29. Branford, S. et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472-3475 (2002).
30. Fischlechner, M. et al. Evolution of enzyme catalysts caged in biomimetic gel-shell beads. Nat. Chem. 6, 791-796 (2014).
31. Tawfik, D. S. & Griffiths, A. D. Man-made cell-like compartments for molecular evolution. Nat. Biotechnol. 16, 652-656 (1998).
32. Yi, L. et al. Engineering of TEV protease variants by yeast ER sequestration screening (YESS) of combinatorial libraries. Proc. Natl. Acad. Sci. USA 110, 7229-7234 (2013).
33. Romanini, D. W., Peralta-Yahya, P., Mondol, V. & Cornish, V. W. A Heritable Recombination system for synthetic Darwinian evolution in yeast. ACS Synth. Biol. 1, 602-609 (2012).
34. Esvelt, K. M., Carlson, J. C. & Liu, D. R. A system for the continuous directed evolution of biomolecules. Nature 472, 499-503 (2011).
35. Yu, K., Roy, D., Bayramyan, M., Haworth, I. S. & Lieber, M. R. Fine-structure analysis of activation-induced deaminase accessibility to class switch region R-loops. Mol. Cell. Biol. 25, 1730-1736 (2005).
36. Schrader, C. E. et al. Mutations occur in the Ig Smu region but rarely in Sgamma regions prior to class switch recombination. EMBO J. 22, 5893-5903 (2003).
37. Yu, K., Chedin, F., Hsieh, C. L., Wilson, T. E. & Lieber, M. R. R-loops at immunoglobulin class switch regions in the chromosomes of stimulated B cells. Nat. Immunol. 4, 442-451 (2003).
38. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420-424 (2016).
39. Tewhey, R. et al. Direct identification of hundreds of expression-modulating variants using a multiplexed reporter assay. Cell 165, 1519-1529 (2016).
40. Findlay, G. M., Boyle, E. A., Hause, R. J., Klein, J. C. & Shendure, J. Saturation editing of genomic regions by multiplex homology-directed repair. Nature 513, 120-123 (2014).
41. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 (2014).
42. Chang, X. & Ma, Y. Q. Using targeted AID-mediated mutagenesis (TAM) to diversify a genomic locus in mammalian cells. Protoc. Exch. http://dx. doi. org/10. 1038/protex. 2016. 062 (2016).
43. Pinello, L. et al. Analyzing CRISPR genome-editing experiments with CRISPResso. Nat. Biotechnol. 34, 695-697 (2016).